Technical Analysis for EQ - Equillium, Inc.

Grade Last Price % Change Price Change
C 7.05 -7.11% -0.54
EQ closed down 7.11 percent on Friday, February 26, 2021, on 64 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down
Historical EQ trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Stochastic Reached Oversold Weakness 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -7.11%
Wide Bands Range Expansion -7.11%
Down 3 Days in a Row Weakness -7.11%
Fell Below 20 DMA Bearish -10.31%
Older End-of-Day Signals for EQ ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Equillium is a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium’s initial product candidate, EQ001 (itolizumab), is a clinical-stage, first-in-class monocolonal antibody that selectively targets the novel immune checkpoint receptor CD6 and is designed to modulate T cells that drive immuno-inflammation. Itolizumab is a clinically-validated therapeutic with a favorable safety and tolerability profile. Equillium plans to advance EQ001 into clinical development in multiple indications of high unmet medical need and believes EQ001 has the potential to be a best-in-class disease modifying therapeutic.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biology Clinical Development Immunology Immune System Monoclonal Antibody Inflammation Antibody Autoimmunity Sutro Biopharma Glycoproteins Immune Checkpoint Inflammatory Disorders

Is EQ a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 27.05
52 Week Low 2.2
Average Volume 752,131
200-Day Moving Average 6.10
50-Day Moving Average 6.54
20-Day Moving Average 8.36
10-Day Moving Average 8.81
Average True Range 0.88
ADX 31.13
+DI 19.85
-DI 29.84
Chandelier Exit (Long, 3 ATRs ) 8.70
Chandelier Exit (Short, 3 ATRs ) 8.24
Upper Bollinger Band 11.18
Lower Bollinger Band 5.53
Percent B (%b) 0.27
BandWidth 67.63
MACD Line 0.45
MACD Signal Line 0.79
MACD Histogram -0.3429
Fundamentals Value
Market Cap 174.33 Million
Num Shares 24.7 Million
EPS -1.41
Price-to-Earnings (P/E) Ratio -4.99
Price-to-Sales 0.00
Price-to-Book 1.56
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.21
Resistance 3 (R3) 8.31 8.02 8.02
Resistance 2 (R2) 8.02 7.73 7.97 7.95
Resistance 1 (R1) 7.54 7.54 7.39 7.44 7.89
Pivot Point 7.25 7.25 7.18 7.20 7.25
Support 1 (S1) 6.76 6.95 6.62 6.66 6.21
Support 2 (S2) 6.47 6.77 6.42 6.15
Support 3 (S3) 5.99 6.47 6.08
Support 4 (S4) 5.89